JP5563296B2 - 二次性副甲状腺機能亢進症の治療及び予防方法 - Google Patents
二次性副甲状腺機能亢進症の治療及び予防方法 Download PDFInfo
- Publication number
- JP5563296B2 JP5563296B2 JP2009516725A JP2009516725A JP5563296B2 JP 5563296 B2 JP5563296 B2 JP 5563296B2 JP 2009516725 A JP2009516725 A JP 2009516725A JP 2009516725 A JP2009516725 A JP 2009516725A JP 5563296 B2 JP5563296 B2 JP 5563296B2
- Authority
- JP
- Japan
- Prior art keywords
- hydroxyvitamin
- vitamin
- compound
- hormone
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 title claims description 25
- 238000000034 method Methods 0.000 title description 28
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 195
- 229930003316 Vitamin D Natural products 0.000 claims description 189
- 235000019166 vitamin D Nutrition 0.000 claims description 189
- 239000011710 vitamin D Substances 0.000 claims description 189
- 229940046008 vitamin d Drugs 0.000 claims description 189
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 167
- 235000021318 Calcifediol Nutrition 0.000 claims description 88
- 229940088597 hormone Drugs 0.000 claims description 75
- 239000005556 hormone Substances 0.000 claims description 75
- JWUBBDSIWDLEOM-XHQRYOPUSA-N (3e)-3-[(2e)-2-[1-(6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2\C1=C\C=C1/CC(O)CCC1=C JWUBBDSIWDLEOM-XHQRYOPUSA-N 0.000 claims description 68
- 210000004369 blood Anatomy 0.000 claims description 58
- 239000008280 blood Substances 0.000 claims description 58
- -1 25-hydroxyvitamin D compound Chemical class 0.000 claims description 51
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 claims description 50
- 208000020832 chronic kidney disease Diseases 0.000 claims description 43
- 238000011282 treatment Methods 0.000 claims description 35
- 230000036765 blood level Effects 0.000 claims description 32
- 239000003814 drug Substances 0.000 claims description 28
- 229940079593 drug Drugs 0.000 claims description 25
- JWUBBDSIWDLEOM-NQZHSCJISA-N 25-hydroxy-3 epi cholecalciferol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@H](O)CCC1=C JWUBBDSIWDLEOM-NQZHSCJISA-N 0.000 claims description 24
- 238000013270 controlled release Methods 0.000 claims description 8
- 230000002950 deficient Effects 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 230000002092 calcimimetic effect Effects 0.000 claims description 2
- 239000002694 phosphate binding agent Substances 0.000 claims description 2
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 claims 1
- HKXBNHCUPKIYDM-CGMHZMFXSA-N doxercalciferol Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C HKXBNHCUPKIYDM-CGMHZMFXSA-N 0.000 claims 1
- 210000002966 serum Anatomy 0.000 description 78
- 239000000203 mixture Substances 0.000 description 38
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 26
- 239000011575 calcium Substances 0.000 description 26
- 229910052791 calcium Inorganic materials 0.000 description 26
- 238000009472 formulation Methods 0.000 description 26
- 150000001875 compounds Chemical class 0.000 description 24
- 238000009256 replacement therapy Methods 0.000 description 21
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 21
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 20
- 239000011574 phosphorus Substances 0.000 description 20
- 229910052698 phosphorus Inorganic materials 0.000 description 20
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 20
- 238000002657 hormone replacement therapy Methods 0.000 description 19
- 102000003982 Parathyroid hormone Human genes 0.000 description 18
- 108090000445 Parathyroid hormone Proteins 0.000 description 18
- 239000000199 parathyroid hormone Substances 0.000 description 18
- 229960001319 parathyroid hormone Drugs 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 17
- 210000003734 kidney Anatomy 0.000 description 16
- 230000009469 supplementation Effects 0.000 description 15
- 230000003834 intracellular effect Effects 0.000 description 14
- 102000009310 vitamin D receptors Human genes 0.000 description 14
- 108050000156 vitamin D receptors Proteins 0.000 description 14
- 230000007423 decrease Effects 0.000 description 13
- 108010073030 25-Hydroxyvitamin D3 1-alpha-Hydroxylase Proteins 0.000 description 12
- 102100036285 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial Human genes 0.000 description 12
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- KJKIIUAXZGLUND-ICCVIKJNSA-N 25-hydroxyvitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C KJKIIUAXZGLUND-ICCVIKJNSA-N 0.000 description 11
- 239000002775 capsule Substances 0.000 description 10
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 230000003111 delayed effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 238000012423 maintenance Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 230000000849 parathyroid Effects 0.000 description 7
- 230000005856 abnormality Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000011278 co-treatment Methods 0.000 description 6
- 239000007903 gelatin capsule Substances 0.000 description 6
- 201000005991 hyperphosphatemia Diseases 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000013268 sustained release Methods 0.000 description 6
- 239000012730 sustained-release form Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 235000005282 vitamin D3 Nutrition 0.000 description 6
- 239000011647 vitamin D3 Substances 0.000 description 6
- 229940021056 vitamin d3 Drugs 0.000 description 6
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 5
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 5
- ZGLHBRQAEXKACO-XJRQOBMKSA-N 1alpha,25-dihydroxyvitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C ZGLHBRQAEXKACO-XJRQOBMKSA-N 0.000 description 5
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 5
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 238000011260 co-administration Methods 0.000 description 5
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 239000006186 oral dosage form Substances 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 108010004103 Chylomicrons Proteins 0.000 description 4
- 208000037147 Hypercalcaemia Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000009102 absorption Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000004097 bone metabolism Effects 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000013632 homeostatic process Effects 0.000 description 4
- 238000005805 hydroxylation reaction Methods 0.000 description 4
- 230000000148 hypercalcaemia Effects 0.000 description 4
- 208000030915 hypercalcemia disease Diseases 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000000412 Avitaminosis Diseases 0.000 description 3
- 206010021135 Hypovitaminosis Diseases 0.000 description 3
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229960002061 ergocalciferol Drugs 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 235000001892 vitamin D2 Nutrition 0.000 description 3
- 239000011653 vitamin D2 Substances 0.000 description 3
- 208000030401 vitamin deficiency disease Diseases 0.000 description 3
- ODZFJAXAEXQSKL-USTMCHFFSA-N 1,24(S)-dihydroxyvitamin D2 Chemical compound C([C@@H]([C@]1(CCC2)C)[C@H](C)/C=C/[C@@](C)(O)C(C)C)CC1\C2=C\C=C1\C[C@@H](O)C[C@H](O)C1=C ODZFJAXAEXQSKL-USTMCHFFSA-N 0.000 description 2
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 description 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000029725 Metabolic bone disease Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008416 bone turnover Effects 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011612 calcitriol Substances 0.000 description 2
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 235000014106 fortified food Nutrition 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 235000006486 human diet Nutrition 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 201000006409 renal osteodystrophy Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000875401 Homo sapiens Sterol 26-hydroxylase, mitochondrial Proteins 0.000 description 1
- 101000855326 Homo sapiens Vitamin D 25-hydroxylase Proteins 0.000 description 1
- 206010020590 Hypercalciuria Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010020707 Hyperparathyroidism primary Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 101100275586 Rattus norvegicus Cyp2j3 gene Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102100036325 Sterol 26-hydroxylase, mitochondrial Human genes 0.000 description 1
- 102100026523 Vitamin D 25-hydroxylase Human genes 0.000 description 1
- 102000050760 Vitamin D-binding protein Human genes 0.000 description 1
- 101710179590 Vitamin D-binding protein Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000003668 hormone analog Substances 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000006207 intravenous dosage form Substances 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000004070 kidney hormone Substances 0.000 description 1
- 238000011545 laboratory measurement Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 208000025061 parathyroid hyperplasia Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- YUGCAAVRZWBXEQ-WHTXLNIXSA-N previtamin D3 Chemical compound C=1([C@@H]2CC[C@@H]([C@]2(CCC=1)C)[C@H](C)CCCC(C)C)\C=C/C1=C(C)CC[C@H](O)C1 YUGCAAVRZWBXEQ-WHTXLNIXSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000009703 regulation of cell differentiation Effects 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000020799 vitamin D status Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81514806P | 2006-06-21 | 2006-06-21 | |
| US60/815,148 | 2006-06-21 | ||
| PCT/US2007/071791 WO2008008608A2 (en) | 2006-06-21 | 2007-06-21 | Method of treating and preventing secondary hyperparathyroidism |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014031369A Division JP6023734B2 (ja) | 2006-06-21 | 2014-02-21 | 二次性副甲状腺機能亢進症の治療及び予防方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009541348A JP2009541348A (ja) | 2009-11-26 |
| JP2009541348A5 JP2009541348A5 (enExample) | 2010-08-12 |
| JP5563296B2 true JP5563296B2 (ja) | 2014-07-30 |
Family
ID=38895677
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009516725A Active JP5563296B2 (ja) | 2006-06-21 | 2007-06-21 | 二次性副甲状腺機能亢進症の治療及び予防方法 |
| JP2014031369A Active JP6023734B2 (ja) | 2006-06-21 | 2014-02-21 | 二次性副甲状腺機能亢進症の治療及び予防方法 |
| JP2016199063A Active JP6463714B2 (ja) | 2006-06-21 | 2016-10-07 | 二次性副甲状腺機能亢進症の治療及び予防方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014031369A Active JP6023734B2 (ja) | 2006-06-21 | 2014-02-21 | 二次性副甲状腺機能亢進症の治療及び予防方法 |
| JP2016199063A Active JP6463714B2 (ja) | 2006-06-21 | 2016-10-07 | 二次性副甲状腺機能亢進症の治療及び予防方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US8329677B2 (enExample) |
| EP (4) | EP2679228B1 (enExample) |
| JP (3) | JP5563296B2 (enExample) |
| CA (1) | CA2655499C (enExample) |
| CY (1) | CY1120675T1 (enExample) |
| DK (3) | DK3357496T3 (enExample) |
| ES (3) | ES2497494T3 (enExample) |
| HU (1) | HUE037309T2 (enExample) |
| LT (1) | LT2679228T (enExample) |
| PL (2) | PL2679228T3 (enExample) |
| PT (3) | PT2679228T (enExample) |
| SI (2) | SI2679228T1 (enExample) |
| WO (1) | WO2008008608A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1993559T1 (sl) | 2006-02-03 | 2017-01-31 | Opko Renal, Llc | Zdravljenje nezadostnosti in pomanjkanja vitamina D s 25-hidroksivitaminon D2 in 25-hidroksivitaminom D3 |
| DK3357496T3 (da) | 2006-06-21 | 2020-05-11 | Opko Ireland Global Holdings Ltd | Terapi ved brug af vitamin d-repletteringsmiddel og vitamin d-hormonsubstitutionsmiddel |
| ES3047207T3 (en) | 2007-04-25 | 2025-12-03 | Opko Renal Llc | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
| CA2684778C (en) * | 2007-04-25 | 2017-09-05 | Cytochroma Inc. | Methods and compounds for vitamin d therapy |
| PT2148684E (pt) | 2007-04-25 | 2013-04-19 | Cytochroma Inc | Método de tratamento para a insuficiência e deficiência de vitamina d |
| PT2148661E (pt) * | 2007-04-25 | 2013-03-06 | Proventiv Therapeutics Llc | Composições orais de libertação controlada compreendendo um composto de vitamina d e veículo ceroso |
| CN106853250A (zh) | 2008-04-02 | 2017-06-16 | 赛特克罗公司 | 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒 |
| PL2321273T3 (pl) * | 2008-07-24 | 2015-05-29 | Wisconsin Alumni Res Found | Podawanie 25-hydroksy-witaminy D3 raz w tygodniu w celu utrzymania podwyższonego stężenia we krwi w stanie równowagi farmakokinetycznej |
| US11672809B2 (en) * | 2010-03-29 | 2023-06-13 | Eirgen Pharma Ltd. | Methods and compositions for reducing parathyroid levels |
| WO2013130953A2 (en) * | 2012-03-01 | 2013-09-06 | The Trustees Of Columbia University In The City Of New York | Autism-associated biomarkers and uses thereof |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| WO2017182237A1 (en) | 2016-03-28 | 2017-10-26 | Opko Ireland Global Holdings, Limited | Methods of vitamin d treatment |
| CA3094915A1 (en) | 2018-04-03 | 2019-10-10 | Opko Ireland Global Holdings, Ltd. | Use of calcifediol in bariatric surgery patients |
| CA3128153A1 (en) | 2019-02-06 | 2020-08-13 | Eirgen Pharma Ltd. | Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein |
| JP7408094B2 (ja) * | 2020-04-27 | 2024-01-05 | キョーラク株式会社 | 構造体 |
| IL297885A (en) * | 2020-05-31 | 2023-01-01 | Eirgen Pharma Ltd | Hard capsule dosage form and its uses |
| WO2025094144A1 (en) | 2023-11-02 | 2025-05-08 | Eirgen Pharma Ltd. | Controlling loss of kidney function |
Family Cites Families (244)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3565924A (en) | 1968-07-01 | 1971-02-23 | Wisconsin Alumni Res Found | 25-hydroxycholfcalciferol |
| US3833622A (en) | 1969-03-17 | 1974-09-03 | Upjohn Co | Crystalline 25-hydroxycholecalciferol hydrate and structurally related compounds |
| US3880894A (en) | 1974-05-24 | 1975-04-29 | Wisconsin Alumni Res Found | 1,25-Dihydroxyergocalciferol |
| US4004003A (en) | 1974-08-28 | 1977-01-18 | The Upjohn Company | 25-Hydroxycalciferol compounds for treatment of steroid-induced osteoporosis |
| US4335120A (en) | 1979-03-21 | 1982-06-15 | Hoffmann-La Roche Inc. | Administration of biologically active vitamin D3 and vitamin D2 materials |
| US4230701A (en) | 1979-03-21 | 1980-10-28 | Hoffmann-La Roche Inc. | Administration of biologically active vitamin D3 and vitamin D2 materials |
| JPS55139320A (en) | 1979-04-16 | 1980-10-31 | Teijin Ltd | Bone metabolism regulator |
| US4442093A (en) | 1981-05-15 | 1984-04-10 | Kureha Kagaku Kogyo Kabushiki Kaisha | Method for administering 24,25-dihydroxycholecalciferol to persons suffering from hypercalcemia |
| JPS57188520A (en) | 1981-05-15 | 1982-11-19 | Kureha Chem Ind Co Ltd | Antihyperkalemia |
| JPS5832823A (ja) | 1981-08-20 | 1983-02-25 | Chugai Pharmaceut Co Ltd | 脱癌剤 |
| JPS58206524A (ja) | 1982-05-26 | 1983-12-01 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| US4448721A (en) | 1982-09-20 | 1984-05-15 | Wisconsin Alumni Research Foundation | Hydroxyvitamin D2 compounds and process for preparing same |
| US4721613A (en) | 1982-12-13 | 1988-01-26 | Alza Corporation | Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use |
| JPS59155309A (ja) | 1983-02-22 | 1984-09-04 | Teijin Ltd | 活性型ビタミンｄ↓３類組成物 |
| US4684524A (en) | 1984-03-19 | 1987-08-04 | Alza Corporation | Rate controlled dispenser for administering beneficial agent |
| US4555364A (en) | 1984-11-01 | 1985-11-26 | Wisconsin Alumni Research Foundation | Method for preparing 1-hydroxyvitamin D compounds |
| US4695591A (en) | 1985-03-29 | 1987-09-22 | Schering Corporation | Controlled release dosage forms comprising hydroxypropylmethylcellulose |
| US4668517A (en) | 1985-04-04 | 1987-05-26 | Norwich Eaton Pharmaceuticals, Inc. | Furazolidone dosage form |
| EP0207638B1 (en) | 1985-06-04 | 1990-12-19 | Teijin Limited | Sustained-release pharmaceutical preparation |
| JPS61293911A (ja) | 1985-06-24 | 1986-12-24 | Teisan Seiyaku Kk | 徐放化製剤 |
| US4892821A (en) | 1987-07-08 | 1990-01-09 | Taisho Pharmaceutical Co., Ltd. | Method for preparing vitamin D compounds |
| US4997824A (en) | 1987-07-22 | 1991-03-05 | Teva Pharmaceutical Industries Ltd. | Combination of cholecalciferol derivatives for the treatment of renal bone disease |
| US5869473A (en) | 1988-08-02 | 1999-02-09 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| US5602116A (en) | 1988-08-02 | 1997-02-11 | Bone Care International, Inc. | Method for treating and preventing secondary hyperparathyroidism |
| US5104864A (en) | 1988-08-02 | 1992-04-14 | Bone Care International, Inc. | Method for treating and preventing loss of bone mass |
| JP2893191B2 (ja) | 1988-11-08 | 1999-05-17 | 武田薬品工業株式会社 | 放出制御性マトリックス剤 |
| JP2525478B2 (ja) | 1989-03-01 | 1996-08-21 | 帝人株式会社 | 安定性の改良された活性型ビタミンｄ▲下３▼類固型製剤 |
| JPH02240024A (ja) | 1989-03-13 | 1990-09-25 | Ss Pharmaceut Co Ltd | 活性型ビタミンｄ↓３類製剤用組成物 |
| US5026559A (en) | 1989-04-03 | 1991-06-25 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
| GB9004544D0 (en) | 1990-03-01 | 1990-04-25 | Leo Pharm Prod Ltd | Novel treatment ii |
| JP2845342B2 (ja) | 1990-04-28 | 1999-01-13 | 大正製薬株式会社 | ビタミンｄ▲下３▼誘導体含有固形製剤組成物 |
| JPH04198129A (ja) | 1990-11-28 | 1992-07-17 | Sumitomo Pharmaceut Co Ltd | 活性型ビタミンｄ↓３類含有組成物 |
| JP2893140B2 (ja) | 1990-11-30 | 1999-05-17 | エスエス製薬株式会社 | 安定なビタミンｄ製剤 |
| JPH04288016A (ja) | 1991-03-14 | 1992-10-13 | Tokai Capsule Kk | 活性型ビタミンｄ３類軟カプセル剤の製造方法 |
| DE69214704T2 (de) | 1991-04-09 | 1997-04-17 | Takeda Chemical Industries Ltd | Stabilisiertes Vitamin D Arzneimittel |
| US5693615A (en) | 1991-06-05 | 1997-12-02 | The Procter & Gamble Company | Therapeutic compositions for osteoinduction |
| US6001884A (en) | 1991-08-23 | 1999-12-14 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6313146B1 (en) | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6031003A (en) | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| US5472712A (en) | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| US5160742A (en) | 1991-12-31 | 1992-11-03 | Abbott Laboratories | System for delivering an active substance for sustained release |
| JP3722832B2 (ja) | 1992-06-22 | 2005-11-30 | ルーナー、コーポレーション | 経口用１α−ヒドロキシプレビタミンＤ |
| US5795882A (en) | 1992-06-22 | 1998-08-18 | Bone Care International, Inc. | Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations |
| US5354743A (en) | 1992-09-15 | 1994-10-11 | Thys Jacobs Susan | Method for the treatment of premenstrual syndrome with vitamin D |
| US5431917A (en) | 1992-10-08 | 1995-07-11 | Japan Elanco Company, Ltd. | Hard capsule for pharmaceutical drugs and method for producing the same |
| US5342626A (en) | 1993-04-27 | 1994-08-30 | Merck & Co., Inc. | Composition and process for gelatin-free soft capsules |
| JP2684587B2 (ja) | 1993-06-21 | 1997-12-03 | 呉羽化学工業株式会社 | 腎性骨異栄養症における骨量減少抑制剤 |
| US6121469A (en) | 1993-12-23 | 2000-09-19 | The Regents Of The University Of California | Therapeutically effective 1α,25-dihydroxyvitamin D3 analogs |
| JPH07242550A (ja) * | 1994-03-02 | 1995-09-19 | Teijin Ltd | 二次性副甲状腺機能亢進症治療剤 |
| IL110117A0 (en) | 1994-06-24 | 1994-10-07 | Univ Ben Gurion | Pharmaceutical compositions comprising vitamin-d analogs |
| SE9402422D0 (sv) | 1994-07-08 | 1994-07-08 | Astra Ab | New beads for controlled release and a pharmaceutical preparation containing the same |
| JPH10504291A (ja) | 1994-07-22 | 1998-04-28 | ジー．ディー．サール アンド カンパニー | 自己乳化性ドラッグデリバリーシステム |
| JPH0892098A (ja) | 1994-09-27 | 1996-04-09 | Teijin Ltd | 肺結核治療剤 |
| HU228150B1 (en) | 1994-10-21 | 2012-12-28 | Nps Pharma Inc | Calcium receptor-active compounds, medicaments comprising them, and the use of said medicaments |
| US5756123A (en) | 1994-12-01 | 1998-05-26 | Japan Elanco Co., Ltd. | Capsule shell |
| US6242434B1 (en) | 1997-08-08 | 2001-06-05 | Bone Care International, Inc. | 24-hydroxyvitamin D, analogs and uses thereof |
| US6376479B1 (en) | 1995-04-03 | 2002-04-23 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| US20040043971A1 (en) | 1995-04-03 | 2004-03-04 | Bone Care International, Inc. | Method of treating and preventing hyperparathyroidism with active vitamin D analogs |
| US20020183288A1 (en) * | 1995-04-03 | 2002-12-05 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| WO1997011053A1 (en) | 1995-09-21 | 1997-03-27 | Wisconsin Alumni Research Foundation | Calcitriol derivatives and their uses |
| DE19549243A1 (de) | 1995-12-21 | 1997-06-26 | Schering Ag | Pharmazeutische Präparate enthaltend Clathrate von Cyclodextrinen und nichtnatürliche Vitamin D-Analoga |
| NO971934L (no) | 1996-05-23 | 1997-11-24 | Hoffmann La Roche | Flourinerte vitamin D3 -analoger |
| US5939408A (en) | 1996-05-23 | 1999-08-17 | Hoffman-La Roche Inc. | Vitamin D3 analogs |
| EP0949927B1 (en) | 1996-08-26 | 2002-10-16 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol |
| US5958451A (en) | 1996-09-03 | 1999-09-28 | Yung Shin Pharm Ind. Co., Ltd. | Process for producing porous, controlled-release capsules and encapsulated composition |
| US5976784A (en) | 1996-09-20 | 1999-11-02 | Wisconsin Alumni Research Foundation | Calcitriol derivatives and their uses |
| ES2565163T3 (es) | 1996-10-28 | 2016-03-31 | General Mills, Inc. | Imbibición y encapsulación de partículas de liberación controlada y producto encapsulado |
| US8828432B2 (en) | 1996-10-28 | 2014-09-09 | General Mills, Inc. | Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles |
| JPH10158171A (ja) | 1996-12-02 | 1998-06-16 | Kita:Kk | ビタミンｄ化合物を配合した眼内投与剤 |
| US6503893B2 (en) | 1996-12-30 | 2003-01-07 | Bone Care International, Inc. | Method of treating hyperproliferative diseases using active vitamin D analogues |
| US20020128240A1 (en) | 1996-12-30 | 2002-09-12 | Bone Care International, Inc. | Treatment of hyperproliferative diseases using active vitamin D analogues |
| US20030129194A1 (en) | 1997-02-13 | 2003-07-10 | Bone Care International, Inc. | Targeted therapeutic delivery of vitamin D compounds |
| US6034075A (en) | 1997-03-20 | 2000-03-07 | The Trustees Of Columbia University In The City Of New York | Method of treating polycystic ovarian syndrome |
| US5872113A (en) | 1997-05-16 | 1999-02-16 | Syntex (U.S.A.) Inc. | Fluorinated vitamin D3 analogs |
| DE69834195T2 (de) | 1997-07-02 | 2007-03-29 | Euro-Celtique S.A. | Stabilisierte tramadol formulierungen mit verzögerter freisetzung |
| JPH1175863A (ja) | 1997-07-10 | 1999-03-23 | Kyowa Hakko Kogyo Co Ltd | ２５−ヒドロキシビタミンＤ３−１α−水酸化酵素および該酵素をコードするＤＮＡ |
| US6096876A (en) | 1997-08-06 | 2000-08-01 | Shriners Hospitals For Children | 1-α-hydroxylase materials and methods |
| US20020076442A1 (en) | 1997-09-02 | 2002-06-20 | Martin Burke | Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders |
| US5919986A (en) | 1997-10-17 | 1999-07-06 | Hoffmann-La Roche Inc. | D-homo vitamin D3 derivatives |
| JPH11158074A (ja) | 1997-12-03 | 1999-06-15 | Hayashi Tomie | 高アミノ酸付加活性型ビタミンｄ強化組成物 |
| US20030059471A1 (en) | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
| WO1999049027A1 (en) * | 1998-03-25 | 1999-09-30 | Cutanogen, Inc. | Methods for prevention and treatment of cancer |
| EP2340840B1 (en) * | 1998-03-27 | 2012-08-29 | Oregon Health Sciences University | Pulse dose Vitamin D drug for the treatment of hyperproliferative skin diseases |
| US6197340B1 (en) | 1998-05-28 | 2001-03-06 | Medical Research Institute | Controlled release lipoic acid |
| US8133694B2 (en) | 1998-06-25 | 2012-03-13 | Immundiagnostik Ag | Functional vitamin D derivatives and method of determining 25-hydroxy- and 1α, 25-dihydroxy vitamin D |
| US6214376B1 (en) | 1998-08-25 | 2001-04-10 | Banner Pharmacaps, Inc. | Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture |
| SI1039882T1 (sl) | 1998-08-27 | 2011-01-31 | Pfizer Health Ab | Terapevtska formulacija za dajanje tolterodina s kontroliranim sproščanjem |
| SE9803871D0 (sv) | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
| US6139875A (en) | 1998-09-29 | 2000-10-31 | Eastman Chemical Company | Aqueous enteric coating composition and low gastric permeability enteric coating |
| WO2000018374A1 (en) | 1998-10-01 | 2000-04-06 | Elan Pharma International, Ltd. | Controlled release nanoparticulate compositions |
| DE69940821D1 (de) | 1998-10-09 | 2009-06-10 | Gen Mills Inc | Verkapselung empfindlicher flüssiger komponenten in eine matrix zur gewinnung diskreter lagerbeständiger partikel |
| JP3449253B2 (ja) | 1998-10-29 | 2003-09-22 | シオノギクオリカプス株式会社 | 硬質カプセルの製造方法 |
| JP2000206312A (ja) | 1998-11-12 | 2000-07-28 | Olympus Optical Co Ltd | 光学素子 |
| AU765909C (en) | 1998-12-17 | 2004-09-23 | Alza Corporation | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
| US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| US6432936B1 (en) | 1999-01-20 | 2002-08-13 | Wisconsin Alumni Research Foundation | Crystalline 1α-hydroxyvitamin D2 and method of purification thereof |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| CA2366586C (en) | 1999-04-01 | 2004-06-22 | Johns Hopkins University | Non-calcemic, antiproliferative, transcriptionally active sulfur-containing analogs of 1.alpha., 25-dihydroxy vitamin d3 |
| US7648826B1 (en) | 1999-04-02 | 2010-01-19 | The Regents Of The University Of California | Detecting CYP24 expression level as a marker for predisposition to cancer |
| DE19916419B4 (de) | 1999-04-08 | 2005-06-16 | Schering Ag | Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose |
| WO2000072831A1 (en) | 1999-05-27 | 2000-12-07 | Drugtech Corporation | Nutritional formulations |
| US6340473B1 (en) | 1999-07-07 | 2002-01-22 | R.P. Scherer Technologies, Inc. | Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
| US6274169B1 (en) | 1999-08-02 | 2001-08-14 | Abbott Laboratories | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
| US6051567A (en) | 1999-08-02 | 2000-04-18 | Abbott Laboratories | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
| DE60045101D1 (de) | 1999-08-31 | 2010-11-25 | Chugai Pharmaceutical Co Ltd | Weichkapseln |
| US20060034937A1 (en) | 1999-11-23 | 2006-02-16 | Mahesh Patel | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| GB0007419D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Gmbh | Composition |
| US6375981B1 (en) | 2000-06-01 | 2002-04-23 | A. E. Staley Manufacturing Co. | Modified starch as a replacement for gelatin in soft gel films and capsules |
| IL153378A0 (en) | 2000-07-18 | 2003-07-06 | Bone Care Internat Inc | STABILIZED 1alpha-HYDROXY VITAMIN D |
| US6491950B1 (en) | 2000-08-07 | 2002-12-10 | Kos Pharmaceuticals, Inc. | Controlled release pharmaceutical composition |
| EP1323404B1 (en) | 2000-08-29 | 2013-10-16 | Nisshin Kasei Co.,Ltd. | Hard capsule |
| US6887493B2 (en) | 2000-10-25 | 2005-05-03 | Adi Shefer | Multi component controlled release system for oral care, food products, nutraceutical, and beverages |
| CN101317825A (zh) | 2000-10-30 | 2008-12-10 | 欧罗赛铁克股份有限公司 | 控释氢可酮制剂 |
| US6479649B1 (en) | 2000-12-13 | 2002-11-12 | Fmc Corporation | Production of carrageenan and carrageenan products |
| JP2002302447A (ja) | 2001-04-03 | 2002-10-18 | Shimizu Pharmaceutical Co Ltd | 局所投与用癌治療剤 |
| CA2446957A1 (en) | 2001-05-15 | 2002-11-21 | Warner-Lambert Company Llc | Compaction process for manufacture of sodium phenytoin dosage form |
| AU2002315779B2 (en) | 2001-07-05 | 2007-03-22 | Wakunaga Pharmaceutical Co.,Ltd | Soft capsules |
| US6870833B2 (en) | 2001-07-20 | 2005-03-22 | Net2Phone, Inc. | Active voice messaging |
| US7166585B2 (en) | 2001-08-22 | 2007-01-23 | Cytochroma Inc. | 24-Sulfur-substituted analogs of 1α,25-dihydroxy vitamin D3 |
| US7033996B2 (en) | 2001-08-31 | 2006-04-25 | University Of Medicine & Dentistry Of New Jersey | Method for the treatment of vitamin D related disease |
| DE10149674A1 (de) | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
| ES2283593T3 (es) | 2001-10-12 | 2007-11-01 | Johns Hopkins University | Analogos de oxima poco calcemicos de 1alfa,25-dihidroxi vitamina d3. |
| US6524788B1 (en) | 2001-11-02 | 2003-02-25 | Thomas L. Cantor | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
| US7056655B2 (en) * | 2001-11-02 | 2006-06-06 | Scantibodies Laboratory, Inc. | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
| ITMI20012366A1 (it) | 2001-11-09 | 2003-05-09 | Farmatron Ltd | Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali |
| JP4184278B2 (ja) | 2001-11-22 | 2008-11-19 | 森下仁丹株式会社 | 非ゼラチン系カプセル皮膜組成物及びそれを用いたカプセル |
| GB0128415D0 (en) | 2001-11-27 | 2002-01-16 | Univ Sheffield | Medicaments |
| US20030191093A1 (en) | 2001-12-03 | 2003-10-09 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
| US6627622B2 (en) | 2002-02-18 | 2003-09-30 | Wisconsin Alumni Research Foundation | (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses |
| FR2829142B1 (fr) | 2001-12-27 | 2004-02-13 | Ulice | Composition filmogene d'heteroxylanes pour la fabrication de capsules ainsi obtenues |
| US7632518B2 (en) | 2002-01-15 | 2009-12-15 | Dsm Ip Assets B.V. | 25-hydroxy vitamin D3 compositions |
| US6949256B2 (en) | 2002-01-18 | 2005-09-27 | Banner Pharmacaps, Inc. | Non-gelatin capsule shell formulation |
| NO20021592D0 (no) | 2002-04-04 | 2002-04-04 | Fmc Biopolymer As | Polysakkaridkapsler og fremgangsmåte ved fremstilling derav |
| WO2003086415A1 (en) | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
| EP1499303A4 (en) | 2002-04-10 | 2007-07-25 | Fred H Miller | MULTIPHASE MULTI-COMPONENT CAPSULE SYSTEM |
| AU2003222699A1 (en) | 2002-05-02 | 2003-11-17 | Cytochroma Inc. | Stable cytochrome p450 24 (cyp24) expressing cell line and methods and uses thereof |
| ATE543796T1 (de) | 2002-06-13 | 2012-02-15 | Univ Johns Hopkins | 24-sulfoximine vitamin d3 derivate |
| CA2491355A1 (en) | 2002-07-05 | 2004-01-15 | Temrel Limited | Controlled release compositions comprising coated pellets having non-uniform coating thicknesses |
| MY142179A (en) | 2002-07-25 | 2010-10-15 | Glaxo Group Ltd | Multicomponent pharmaceutical dosage form |
| CA2494234C (en) | 2002-07-29 | 2009-10-27 | Alza Corporation | Methods and dosage forms for controlled delivery of paliperidone |
| US8268352B2 (en) | 2002-08-05 | 2012-09-18 | Torrent Pharmaceuticals Limited | Modified release composition for highly soluble drugs |
| AU2002368245A1 (en) | 2002-09-26 | 2004-04-19 | Young-Kweon Choi | Matrix type patch for transdermal administration of vitamin d analog and the use thereof |
| US20050101576A1 (en) | 2003-11-06 | 2005-05-12 | Novacea, Inc. | Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes |
| US8999372B2 (en) | 2002-11-14 | 2015-04-07 | Cure Pharmaceutical Corporation | Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use |
| JP2004175750A (ja) | 2002-11-28 | 2004-06-24 | Kose Corp | 皮膚障害抑制剤、皮膚障害改善剤、及びそれらを含有する皮膚外用剤 |
| US20050026877A1 (en) | 2002-12-03 | 2005-02-03 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
| DE10393906T5 (de) | 2002-12-16 | 2006-01-12 | Teva Pharmaceutical Industries Ltd. | Verfahren zur Erhöhung der Bioverfügbarkeit von Alendronat oder einem anderen Bisphosphonat durch Verabreichen einer Vordosis eines Vitamin D-Derivats |
| AU2003292920A1 (en) | 2002-12-18 | 2004-07-09 | Cytochroma Inc. | 25-so2-substituted analogs of 1alpha, 25-dihydroxyvitamin d3 (calcitriol) |
| EP1592410B1 (en) | 2003-02-11 | 2008-07-23 | Alza Corporation | Methods and dosage forms with modified layer geometry |
| US7816341B2 (en) | 2003-04-14 | 2010-10-19 | Fmc Corporation | Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom |
| JP2007528357A (ja) | 2003-04-14 | 2007-10-11 | エフ エム シー コーポレーション | ゲルフィルムを製造するための方法 |
| EP1677802A2 (en) | 2003-04-30 | 2006-07-12 | Bioxell S.p.a. | 1,3 aclyated 24-keto-vitamin d3 compounds and methods of use thereof |
| PL1622629T3 (pl) | 2003-05-07 | 2013-12-31 | Osteologix As | Kompozycja do kontrolowanego uwalniania zawierająca sól strontu |
| EP1479677A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | New indole derivatives as factor xa inhibitors |
| US7207965B2 (en) | 2003-06-16 | 2007-04-24 | Solx, Inc. | Shunt for the treatment of glaucoma |
| JP5628467B2 (ja) | 2003-06-26 | 2014-11-19 | シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａ Ｕｓ， Ｉｎｃ． | 生体分解性徐放性ドラッグデリバリーシステム |
| AU2003903382A0 (en) | 2003-07-03 | 2003-07-17 | Medvet Science Pty Ltd | Inhibition of calcitriol mediated cyp24 induction screening for compounds therefor and uses thereof |
| JP2007525472A (ja) | 2003-07-04 | 2007-09-06 | ニコメド ダンマーク エイピーエス | 経口使用のための副甲状腺ホルモン（ｐｔｈ）含有医薬組成物 |
| US20050124591A1 (en) | 2003-07-29 | 2005-06-09 | Jin Tian | Use of vitamin Ds to treat kidney disease |
| US20050148557A1 (en) | 2003-07-29 | 2005-07-07 | Jin Tian | Use of Vitamin Ds to treat kidney disease |
| US7829595B2 (en) | 2003-09-12 | 2010-11-09 | Amgen Inc. | Rapid dissolution formulation of a calcium receptor-active compound |
| WO2005051396A2 (en) | 2003-11-25 | 2005-06-09 | Deltanoid Pharmaceuticals, Inc. | Methods for reducing body fat using vitamin d compounds |
| CA2494572A1 (en) | 2003-12-19 | 2005-06-19 | Cytochroma Inc. | Cytochrome p450 24 (cyp24) monoclonal antibody and methods and uses thereof |
| US20060009425A1 (en) | 2004-05-28 | 2006-01-12 | Leticia Delgado-Herrera | Oral formulations of paricalcitol |
| WO2005123120A1 (en) | 2004-06-16 | 2005-12-29 | Smart Drug Systems Inc. | Sustained release vaccine composition |
| WO2006007323A2 (en) | 2004-06-28 | 2006-01-19 | Alza Corporation | Dosage forms for low solubility and/or low dissolution rate free acid pharmaceutical agents |
| US20060019933A1 (en) | 2004-07-22 | 2006-01-26 | David Boardman | Process for preparing stabilized vitamin D |
| WO2006010640A1 (en) | 2004-07-29 | 2006-02-02 | Sanofi-Aventis | Pharmaceutical multilayer tablet for controlled release of active ingredients with highly ph-dependent solubility |
| US8231896B2 (en) | 2004-11-08 | 2012-07-31 | R.P. Scherer Technologies, Llc | Non-gelatin soft capsule system |
| WO2006059180A2 (en) | 2004-12-03 | 2006-06-08 | Council Of Scientific And Industrial Research | Process of preparation of biodegradable films from semi refined kappa carrageenan |
| US8318210B2 (en) | 2005-02-28 | 2012-11-27 | Neos Therapeutics, Lp | Compositions and methods of making sustained release liquid formulations |
| US7745226B2 (en) | 2005-04-06 | 2010-06-29 | Quest Diagnostics Investments Incorporated | Methods for detecting vitamin D metabolites |
| US8241664B2 (en) | 2005-04-15 | 2012-08-14 | Clarus Therapeutics, Inc | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
| US20060257481A1 (en) | 2005-04-21 | 2006-11-16 | Decode Genetics Ehf. | Sustained release formulation and dosing schedule of leukotriene synthesis inhibitor for human therapy |
| US9205047B2 (en) | 2005-04-25 | 2015-12-08 | The Governing Council Of The University Of Toronto | Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix |
| US20080134937A1 (en) | 2005-05-25 | 2008-06-12 | Joo Hwan Yang | Cellulose hard capsule enhancing mechanical film strength |
| AR055099A1 (es) | 2005-07-28 | 2007-08-08 | Alza Corp | Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol |
| CA2624124A1 (en) | 2005-09-29 | 2007-04-12 | F. Hoffmann-La Roche Ag | Antibodies against 25-hydroxyvitamin d |
| ITFI20050206A1 (it) | 2005-09-30 | 2007-04-01 | Valpharma Sa | Composizione farmaceutica a rilascio controllato di venlafaxina cloridrato, e processo per la sua preparazione |
| EP1945185B1 (en) | 2005-10-12 | 2016-02-03 | Proventiv Therapeutics, LLC | Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency |
| JP5406529B2 (ja) | 2005-10-26 | 2014-02-05 | バナー ファーマキャプス， インコーポレイテッド | カプセル充墳物としての親油性ベヒクルに基づく二重制御された放出マトリクスシステム |
| CN101360485B (zh) | 2005-10-26 | 2013-04-17 | 班纳制药公司 | 作为胶囊填充物的基于亲水性载体的双重控释基质系统 |
| AP2008004489A0 (en) | 2005-11-01 | 2008-06-30 | Cpkelco U S Inc | Films and capsules made from modified carboxymethycellulose materials and methods of making same |
| WO2007068287A1 (en) | 2005-12-15 | 2007-06-21 | Laboratoria Qualiphar | Sustained release vitamin preparation |
| MXPA05014091A (es) | 2005-12-20 | 2007-06-20 | Leopoldo De Jesus Espinosa Abdala | Composiciones farmaceuticas que comprenden derivados de esteroides sinteticos, minerales y el metabolito activo de la vitamina d, 1,25(oh)2d3 (calcitriol) para la prevencion y tratamiento de la osteoporosis y el control de los sintomas de la menopaus |
| EP1987164A2 (en) | 2006-01-31 | 2008-11-05 | Health Research, Inc. | Method for identifying altered vitamin d metabolism |
| US7528122B2 (en) | 2006-02-02 | 2009-05-05 | Wisconsin Alumni Research Foundation | Vitamin D analog—NEL, methods and uses thereof |
| SI1993559T1 (sl) | 2006-02-03 | 2017-01-31 | Opko Renal, Llc | Zdravljenje nezadostnosti in pomanjkanja vitamina D s 25-hidroksivitaminon D2 in 25-hidroksivitaminom D3 |
| GB0606426D0 (en) | 2006-03-30 | 2006-05-10 | Novartis Ag | Benzimidazole derivatives |
| WO2007146004A1 (en) | 2006-06-06 | 2007-12-21 | Fmc Corporation | Kappa-2 carrageenan composition and products made therefrom |
| US20080109983A1 (en) | 2006-11-10 | 2008-05-15 | Kegel, Llc | Zero Turning Radius Lane Maintenance Machine |
| DK3357496T3 (da) | 2006-06-21 | 2020-05-11 | Opko Ireland Global Holdings Ltd | Terapi ved brug af vitamin d-repletteringsmiddel og vitamin d-hormonsubstitutionsmiddel |
| EP1912400A1 (en) | 2006-10-10 | 2008-04-16 | Matsushita Electric Industrial Co., Ltd. | Method and apparatus for mobile IP route optimization |
| ES2744816T3 (es) | 2006-10-27 | 2020-02-26 | Capsugel Belgium Nv | Cápsulas duras de hidroxipropil metil celulosa y proceso de fabricación |
| US8501717B2 (en) | 2007-02-09 | 2013-08-06 | Merck, Sharp & Dohme Corp. | Methods to treat and/or prevent mucositis |
| US8491937B2 (en) | 2007-02-15 | 2013-07-23 | Wyeth Llc | Stability in vitamin and mineral supplements |
| CN101682239A (zh) | 2007-03-20 | 2010-03-24 | 电锁公司 | 具有导电毡的罗贝尔绕组 |
| EP2136814A4 (en) | 2007-03-21 | 2012-05-30 | Univ Duke | MEDICAL KITS AND FORMULATIONS FOR PREVENTING, TREATING OR REDUCING SECONDARY FRACTURES FROM A PREVIOUS FRACTURE |
| PT2148684E (pt) | 2007-04-25 | 2013-04-19 | Cytochroma Inc | Método de tratamento para a insuficiência e deficiência de vitamina d |
| CA2684778C (en) | 2007-04-25 | 2017-09-05 | Cytochroma Inc. | Methods and compounds for vitamin d therapy |
| PT2148661E (pt) | 2007-04-25 | 2013-03-06 | Proventiv Therapeutics Llc | Composições orais de libertação controlada compreendendo um composto de vitamina d e veículo ceroso |
| ES3047207T3 (en) | 2007-04-25 | 2025-12-03 | Opko Renal Llc | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
| US20090004284A1 (en) | 2007-06-26 | 2009-01-01 | Watson Pharmaceuticals, Inc. | Controlled release tamsulosin hydrochloride formulation |
| KR100836960B1 (ko) | 2007-09-07 | 2008-06-10 | 주식회사 서울제약 | 새로운 나이아신 제어방출형 제제 |
| EP2042165A1 (de) | 2007-09-28 | 2009-04-01 | Swiss Caps Rechte und Lizenzen AG | Hot-Melt-Befüllte Weichkapseln |
| AU2007362356A1 (en) | 2007-12-12 | 2009-06-18 | Northern Innovations And Formulations Corp. | Particles in a capsule |
| US20110039811A1 (en) | 2008-02-12 | 2011-02-17 | Neil Robert Buck | Treating hyperglycemia with 25-hydroxyvitamin d3 |
| US20110039809A1 (en) | 2008-02-13 | 2011-02-17 | Neil Robert Buck | Combined use of 25-hydroxy-vitamin d3 and vitamin d3 for improving bone mineral density and for treating osteoporisis |
| CN101951917A (zh) | 2008-02-13 | 2011-01-19 | 帝斯曼知识产权资产管理有限公司 | 用25-羟基维生素d3治疗高血压 |
| KR101561717B1 (ko) | 2008-02-13 | 2015-10-19 | 디에스엠 아이피 어셋츠 비.브이. | 인간의 근육 생리에 영향을 미치는 25-하이드록시-비타민 ｄ3의 용도 |
| KR20100126375A (ko) | 2008-02-13 | 2010-12-01 | 디에스엠 아이피 어셋츠 비.브이. | 비타민 ｄ와 25-하이드록시비타민 ｄ3의 조합물 |
| CN106853250A (zh) | 2008-04-02 | 2017-06-16 | 赛特克罗公司 | 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒 |
| PL2321273T3 (pl) | 2008-07-24 | 2015-05-29 | Wisconsin Alumni Res Found | Podawanie 25-hydroksy-witaminy D3 raz w tygodniu w celu utrzymania podwyższonego stężenia we krwi w stanie równowagi farmakokinetycznej |
| BRPI0823096B8 (pt) | 2008-09-24 | 2022-07-05 | Evonik Roehm Gmbh | composição farmacêutica de opióide de liberação controlada, dependente do ph, com resistência contra a influência do etanol, processo para sua preparação, e seu uso |
| ES2425762T3 (es) | 2008-10-27 | 2013-10-17 | Roquette Freres | Polímero insoluble en agua: revestimientos de película a base de derivados de almidón modificado para la liberación dirigida al colon |
| MX2011007817A (es) | 2009-01-23 | 2011-09-21 | A F S P A Aziende Chimichi Riunite Angelini Francesco A C R | Formulacion farmaceutica o alimenticia de liberacion controlada y proceso para su preparacion. |
| CH700543A2 (de) | 2009-03-03 | 2010-09-15 | Innogel Ag | Film auf Basis von Stärke. |
| WO2011031621A2 (en) | 2009-09-10 | 2011-03-17 | Fmc Corporation | High strength seamless alginate capsules |
| IT1396937B1 (it) | 2009-11-26 | 2012-12-20 | Bruzzese | Formulazioni di bisfosfonati e vitamina d idonee alla somministrazione intermittente per via intramuscolare e sottocutanea |
| FR2953139B1 (fr) | 2009-11-27 | 2012-04-13 | Servier Lab | Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine |
| US8101204B2 (en) | 2010-01-14 | 2012-01-24 | Karl Wei Cao | Hard capsule composition and method of use |
| US8101203B2 (en) | 2010-01-14 | 2012-01-24 | Karl Wei Cao | Hard capsule composition and method of use |
| WO2011095388A1 (en) | 2010-02-04 | 2011-08-11 | Synthon Bv | Tolterodine bead |
| US11672809B2 (en) | 2010-03-29 | 2023-06-13 | Eirgen Pharma Ltd. | Methods and compositions for reducing parathyroid levels |
| KR20120005228A (ko) | 2010-07-08 | 2012-01-16 | 주식회사 네비팜 | 골다공증 치료용 비스포스폰산 함유 장용 약학조성물 및 그의 제조방법 |
| EP2600849B1 (en) | 2010-08-04 | 2016-03-30 | R.P. Scherer Technologies, LLC | Film-forming composition for soft capsules |
| US20120135103A1 (en) | 2010-11-30 | 2012-05-31 | Mead Johnson Nutrition Company | Staged Infant Feeding Regimen To Promote Healthy Development And Growth |
| CN106924268A (zh) | 2010-12-06 | 2017-07-07 | 帝斯曼知识产权资产管理有限公司 | 用25‑羟基‑维生素d3治疗与嗜酸性粒细胞趋化因子增高有关的病症 |
| CA2821415C (en) | 2010-12-28 | 2017-08-01 | Future Diagnostics B.V. | Release reagent for vitamin d |
| DK2680826T3 (en) | 2011-03-02 | 2017-10-09 | D3 Pharma Ltd | VITAMIN D COMPOSITION |
| WO2012144789A2 (ko) | 2011-04-20 | 2012-10-26 | 주식회사 서흥캅셀 | 붕해도 및 피막 경도를 개선한 비동물성 연질 캡슐 피막 조성물 |
| BR112013026929A2 (pt) | 2011-04-20 | 2016-12-27 | Mico Bio Inc | composição e método para intensificação de uma resposta imune |
| CN102771688A (zh) | 2011-05-13 | 2012-11-14 | 富曼实（上海）商贸有限公司 | 可食用液体填充的多糖胶囊 |
| US20130085121A1 (en) | 2011-09-30 | 2013-04-04 | Jianguo Wang | Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d |
| WO2014029953A1 (en) | 2012-08-21 | 2014-02-27 | Cipla Limited | Hot melt extruded (hme) pharmaceutical composition of cinacalcet |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| PT106978A (pt) | 2013-05-31 | 2014-12-02 | Tecnimede Sociedade Tecnico Medicinal S A | Composição sólida oral contendo ácido ibandrónico e vitamina d |
| EP2815745A1 (en) | 2013-06-21 | 2014-12-24 | Swiss Caps Rechte und Lizenzen AG | Soft shell capsule and process for its manufacture |
| CN103495176B (zh) | 2013-10-26 | 2015-01-28 | 中山市凯博思淀粉材料科技有限公司 | 一种共混挤出法制备淀粉基软胶囊的方法 |
| CN103520133B (zh) | 2013-10-26 | 2015-02-04 | 中山市凯博思淀粉材料科技有限公司 | 一种淀粉基软胶囊的制备方法 |
| PE20170392A1 (es) | 2014-08-07 | 2017-04-07 | Opko Ireland Global Holdings Ltd | Terapia adjuntiva con 25-hidroxi vitamina d |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
-
2007
- 2007-06-21 DK DK18162510.4T patent/DK3357496T3/da active
- 2007-06-21 HU HUE13177274A patent/HUE037309T2/hu unknown
- 2007-06-21 SI SI200732029T patent/SI2679228T1/en unknown
- 2007-06-21 ES ES07840277.3T patent/ES2497494T3/es active Active
- 2007-06-21 DK DK07840277.3T patent/DK2037936T3/da active
- 2007-06-21 LT LTEP13177274.1T patent/LT2679228T/lt unknown
- 2007-06-21 ES ES18162510T patent/ES2791535T3/es active Active
- 2007-06-21 EP EP13177274.1A patent/EP2679228B1/en active Active
- 2007-06-21 EP EP18162510.4A patent/EP3357496B1/en active Active
- 2007-06-21 SI SI200731501T patent/SI2037936T1/sl unknown
- 2007-06-21 PL PL13177274T patent/PL2679228T3/pl unknown
- 2007-06-21 US US12/305,572 patent/US8329677B2/en active Active
- 2007-06-21 PT PT131772741T patent/PT2679228T/pt unknown
- 2007-06-21 ES ES13177274.1T patent/ES2670029T3/es active Active
- 2007-06-21 WO PCT/US2007/071791 patent/WO2008008608A2/en not_active Ceased
- 2007-06-21 PT PT181625104T patent/PT3357496T/pt unknown
- 2007-06-21 DK DK13177274.1T patent/DK2679228T3/en active
- 2007-06-21 EP EP20151076.5A patent/EP3659608A1/en active Pending
- 2007-06-21 CA CA2655499A patent/CA2655499C/en active Active
- 2007-06-21 JP JP2009516725A patent/JP5563296B2/ja active Active
- 2007-06-21 EP EP07840277.3A patent/EP2037936B1/en active Active
- 2007-06-21 PT PT78402773T patent/PT2037936E/pt unknown
- 2007-06-21 PL PL07840277T patent/PL2037936T3/pl unknown
-
2012
- 2012-11-19 US US13/680,997 patent/US9402855B2/en active Active
-
2014
- 2014-02-21 JP JP2014031369A patent/JP6023734B2/ja active Active
-
2016
- 2016-07-27 US US15/220,963 patent/US9913852B2/en active Active
- 2016-10-07 JP JP2016199063A patent/JP6463714B2/ja active Active
-
2018
- 2018-03-12 US US15/918,620 patent/US10668089B2/en active Active
- 2018-04-18 CY CY181100415T patent/CY1120675T1/el unknown
-
2020
- 2020-04-24 US US16/858,395 patent/US11452734B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6463714B2 (ja) | 二次性副甲状腺機能亢進症の治療及び予防方法 | |
| EP3225243B1 (en) | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease | |
| ES2496915T3 (es) | Composiciones orales de liberación controlada que comprenden un compuesto de vitamina D y un soporte céreo | |
| EP3636280B1 (en) | Methods and compositions for reducing parathyroid levels | |
| JP2025031720A (ja) | カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物 | |
| HK1259602B (en) | Therapy using vitamin d repletion agent and vitamin d hormone replacement agent | |
| HK1193049A (en) | Therapy using vitamin d repletion agent and vitamin d hormone replacement agent | |
| HK1193049B (en) | Therapy using vitamin d repletion agent and vitamin d hormone replacement agent | |
| EP4326279A1 (en) | Universal dosage regime of 25-hydroxy vitamin d3 | |
| CN115397432A (zh) | 25-羟基维生素d2和/或d3用于肥胖症 | |
| US20050239756A1 (en) | Methods of treating various vitamin D metabolism conditions with 1alpha-hydroxyvitamin D2 | |
| HK1174538B (en) | Oral controlled release compositions comprising vitamin d compound and waxy carrier | |
| HK1205936B (zh) | 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的方法和组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100618 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100618 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120910 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121207 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121214 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130311 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131021 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140221 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140404 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140410 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140528 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140612 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5563296 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |